| Rheumatoid Arthritis
Celebrex vs Rasuvo
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Celebrex vs Rasuvo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRasuvo has a higher rate of injection site reactions vs Celebrex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rasuvo but not Celebrex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Celebrex
Rasuvo
At A Glance
Oral
Once or twice daily
COX-2 inhibitor
SC injection
Once weekly
Folate analog metabolic inhibitor
Indications
- Degenerative polyarthritis
- Rheumatoid Arthritis
- Juvenile rheumatoid arthritis
- Ankylosing spondylitis
- Primary dysmenorrhea
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Psoriasis
Dosing
Degenerative polyarthritis 200 mg once daily or 100 mg twice daily, oral.
Rheumatoid Arthritis 100 mg to 200 mg twice daily, oral.
Juvenile rheumatoid arthritis 50 mg twice daily for patients 10-25 kg; 100 mg twice daily for patients >25 kg, oral.
Ankylosing spondylitis 200 mg once daily or 100 mg twice daily, oral; if no effect after 6 weeks, may trial 400 mg daily.
Primary dysmenorrhea 400 mg initially, followed by 200 mg if needed on day 1; 200 mg twice daily on subsequent days, oral.
Rheumatoid Arthritis 7.5 mg SC once weekly as starting dose; adjust gradually to achieve optimal response; doses greater than 20 mg/wk associated with increased serious toxicity; available doses 7.5-30 mg in 2.5 mg increments.
Juvenile polyarthritis 10 mg/m2 SC once weekly as starting dose; adjust gradually to achieve optimal response.
Psoriasis 10-25 mg SC once weekly as starting dose; adjust gradually; do not ordinarily exceed 30 mg/week; reduce to lowest effective dose and longest possible rest period once optimal response achieved.
Contraindications
- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib or any components of the drug product
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
- Setting of CABG surgery
- Demonstrated allergic-type reactions to sulfonamides
- Pregnancy
- Alcoholism, alcoholic liver disease, or other chronic liver disease
- Overt or laboratory evidence of immunodeficiency syndromes
- Preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia
- Known hypersensitivity to methotrexate
Adverse Reactions
Most common (>=2%) Headache, dyspepsia, upper respiratory infection, diarrhea, sinusitis, abdominal pain, nausea, back pain, peripheral edema, rhinitis, pharyngitis, rash, flatulence, dizziness, insomnia.
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity.
Postmarketing Vasculitis, deep venous thrombosis, angioedema, liver necrosis, hepatic failure, agranulocytosis, aplastic anemia, pancytopenia, aseptic meningitis, fatal intracranial hemorrhage, interstitial nephritis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, AGEP, fixed drug eruption.
Most common (>=10%) Elevated liver function tests, nausea, vomiting
Serious Ulcerative stomatitis, leukopenia, hepatotoxicity, bone marrow suppression, interstitial pneumonitis, opportunistic infections, embryo-fetal toxicity, malignant lymphomas
Pharmacology
Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin synthesis in peripheral tissues and the CNS, producing analgesic, anti-inflammatory, and antipyretic effects; at therapeutic doses it does not inhibit platelet aggregation or prolong bleeding time.
Methotrexate is a folate analog metabolic inhibitor that inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair, and cellular replication; in rheumatoid arthritis the mechanism may involve immune function modulation, and in psoriasis it exploits the differential in epithelial cell proliferation rates.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Celebrex
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (4/12) · Qty limit (11/12)
Rasuvo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Celebrex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Rasuvo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Celebrex
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Rasuvo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Celebrex.
No savings programs available for Rasuvo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CelebrexView full Celebrex profile
RasuvoView full Rasuvo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.